GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2008

Chemizon Invests in KRIBB to Form Spin-Out

  • Chemizon will collaborate with the Korean Research Institute of Bioscience and Biotechnology (KRIBB) to spin out a biotech company to be called NuCo. NuCo’s goal is to create a pipeline of protein, antibody, and small molecule therapeutics aimed primarily at oncology, CNS, and infectious disease indications. The company will work on target discovery and validation, proteomics, biomarkers, translational medicine research, stem cell biology, diagnostics, and bioinformatics.

    Chemizon’s private equity fund, Chemizon-Oakwood Bioventures, will serve as the lead investor. The firm plans to work closely with KRIBB to capitalize, build a world-class management team, and incubate the company.

    Additionally, Chemizon will use its drug discovery platform to help NuCo convert research into small molecule therapeutics.  “This will allow KRIBB,” points out Sang Ki Rhee, Ph.D., president and CEO of KRIBB, “to focus on basic research without distraction and reduce its considerable dependence on the government for research funding.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?